Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

Variable ability of rapid tests to detect Mycobacterium tuberculosis rpoB mutations conferring phenotypically occult rifampicin resistance.

Torrea G, Ng KCS, Van Deun A, André E, Kaisergruber J, Ssengooba W, Desmaretz C, Gabriels S, Driesen M, Diels M, Asnong S, Fissette K, Gumusboga M, Rigouts L, Affolabi D, Joloba M, De Jong BC.

Sci Rep. 2019 Aug 14;9(1):11826. doi: 10.1038/s41598-019-48401-z.

2.

Multidrug-resistant tuberculosis.

Chiang CY, Van Deun A, Trébucq A, Piubello A, Schwoebel V, Rieder HL.

Lancet. 2019 Jul 27;394(10195):299. doi: 10.1016/S0140-6736(19)30046-7. No abstract available. Erratum in: Lancet. 2019 Aug 17;394(10198):564.

PMID:
31354138
3.

Outcome definitions for multidrug-resistant tuberculosis treated with shorter treatment regimens.

Schwoebel V, Chiang CY, Trébucq A, Piubello A, Aït-Khaled N, Koura KG, Heldal E, Van Deun A, Rieder HL.

Int J Tuberc Lung Dis. 2019 May 1;23(5):619-624. doi: 10.5588/ijtld.18.0798.

PMID:
31097072
4.

A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis.

Nunn AJ, Phillips PPJ, Meredith SK, Chiang CY, Conradie F, Dalai D, van Deun A, Dat PT, Lan N, Master I, Mebrahtu T, Meressa D, Moodliar R, Ngubane N, Sanders K, Squire SB, Torrea G, Tsogt B, Rusen ID; STREAM Study Collaborators.

N Engl J Med. 2019 Mar 28;380(13):1201-1213. doi: 10.1056/NEJMoa1811867. Epub 2019 Mar 13.

5.

Twenty years of rifampicin resistance surveillance in Bangladesh: periodic vs. continuous monitoring.

Van Deun A, Aung KJM, Hossain MA, Salim MAH, Gumusboga M, de Jong BC, Decroo T.

Int J Tuberc Lung Dis. 2018 Dec 1;22(12):1450-1461. doi: 10.5588/ijtld.18.0158.

PMID:
30606317
6.

Sputum smear microscopy in the Xpert® MTB/RIF era.

Van Deun A, Tahseen S, Affolabi D, Hossain MA, Joloba ML, Angra PK, Ridderhof JC, de Jong BC, Rieder HL.

Int J Tuberc Lung Dis. 2019 Jan 1;23(1):12-18. doi: 10.5588/ijtld.18.0553. Epub 2018 Dec 19.

PMID:
30567624
7.

Gatifloxacin Pharmacokinetics/Pharmacodynamics-based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant Tuberculosis.

Deshpande D, Pasipanodya JG, Srivastava S, Bendet P, Koeuth T, Bhavnani SM, Ambrose PG, Smythe W, McIlleron H, Thwaites G, Gumusboga M, Van Deun A, Gumbo T.

Clin Infect Dis. 2018 Nov 28;67(suppl_3):S274-S283. doi: 10.1093/cid/ciy618.

PMID:
30496459
8.

Xpert Ultra Can Unambiguously Identify Specific Rifampin Resistance-Conferring Mutations.

Ng KCS, van Deun A, Meehan CJ, Torrea G, Driesen M, Gabriëls S, Rigouts L, André E, de Jong BC.

J Clin Microbiol. 2018 Aug 27;56(9). pii: e00686-18. doi: 10.1128/JCM.00686-18. Print 2018 Sep. No abstract available.

9.

Principles for constructing a tuberculosis treatment regimen: the role and definition of core and companion drugs.

Van Deun A, Decroo T, Piubello A, de Jong BC, Lynen L, Rieder HL.

Int J Tuberc Lung Dis. 2018 Mar 1;22(3):239-245. doi: 10.5588/ijtld.17.0660. Review.

PMID:
29471899
10.

Isoniazid resistance levels of Mycobacterium tuberculosis can largely be predicted by high-confidence resistance-conferring mutations.

Lempens P, Meehan CJ, Vandelannoote K, Fissette K, de Rijk P, Van Deun A, Rigouts L, de Jong BC.

Sci Rep. 2018 Feb 19;8(1):3246. doi: 10.1038/s41598-018-21378-x.

11.

Should gatifloxacin be included in the model list of essential medicines?

Chiang CY, Trébucq A, Piubello A, Rieder HL, Van Deun A.

Eur Respir J. 2018 Feb 7;51(2). pii: 1702329. doi: 10.1183/13993003.02329-2017. Print 2018 Feb. No abstract available.

12.

Comment on: Effects of isoniazid resistance on TB treatment outcomes under programmatic conditions in a high-TB and -HIV setting: a prospective multicentre study.

Decroo T, Van Deun A, Lynen L.

J Antimicrob Chemother. 2018 Jun 1;73(6):1733-1734. doi: 10.1093/jac/dkx497. No abstract available.

PMID:
29293989
13.

Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries.

Trébucq A, Schwoebel V, Kashongwe Z, Bakayoko A, Kuaban C, Noeske J, Hassane S, Souleymane B, Piubello A, Ciza F, Fikouma V, Gasana M, Ouedraogo M, Gninafon M, Van Deun A, Cirillo DM, Koura KG, Rieder HL.

Int J Tuberc Lung Dis. 2018 Jan 1;22(1):17-25. doi: 10.5588/ijtld.17.0498. Epub 2017 Nov 17.

PMID:
29149917
14.

How should discordance between molecular and growth-based assays for rifampicin resistance be investigated?

Hofmann-Thiel S, Hoffmann H, Hillemann D, Rigouts L, Van Deun A, Kranzer K.

Int J Tuberc Lung Dis. 2017 Jul 1;21(7):721-726. doi: 10.5588/ijtld.17.0140.

PMID:
28633695
15.

Shorter regimens for multidrug-resistant tuberculosis should also be applicable in Europe.

Heldal E, Van Deun A, Chiang CY, Rieder HL.

Eur Respir J. 2017 Jun 1;49(6). pii: 1700228. doi: 10.1183/13993003.00228-2017. Print 2017 Jun. No abstract available.

16.

Shortened multidrug-resistant tuberculosis regimens overcome low-level fluoroquinolone resistance.

Van Deun A, Chiang CY.

Eur Respir J. 2017 Jun 1;49(6). pii: 1700223. doi: 10.1183/13993003.00223-2017. Print 2017 Jun. No abstract available.

17.

Rationale for high-dose isoniazid in the treatment of multidrug-resistant tuberculosis.

Rieder HL, Van Deun A.

Int J Tuberc Lung Dis. 2017 Jan 1;21(1):123-124. doi: 10.5588/ijtld.16.0619. No abstract available.

PMID:
28157478
18.

The majority of patients with multidrug-resistant tuberculosis in Sub-Saharan Africa present a concomitant resistance to pyrazinamide.

Daneau G, Gumusboga M, De Rijk P, Trebucq A, Rigouts L, Van Deun A, de Jong BC.

Int J Mycobacteriol. 2016 Dec;5 Suppl 1:S46-S47. doi: 10.1016/j.ijmyco.2016.10.015. Epub 2016 Oct 27.

19.

Twenty Years of Global Surveillance of Antituberculosis-Drug Resistance.

Zignol M, Dean AS, Falzon D, van Gemert W, Wright A, van Deun A, Portaels F, Laszlo A, Espinal MA, Pablos-Méndez A, Bloom A, Aziz MA, Weyer K, Jaramillo E, Nunn P, Floyd K, Raviglione MC.

N Engl J Med. 2016 Sep 15;375(11):1081-9. doi: 10.1056/NEJMsr1512438. No abstract available.

20.

Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method.

Mitnick CD, White RA, Lu C, Rodriguez CA, Bayona J, Becerra MC, Burgos M, Centis R, Cohen T, Cox H, D'Ambrosio L, Danilovitz M, Falzon D, Gelmanova IY, Gler MT, Grinsdale JA, Holtz TH, Keshavjee S, Leimane V, Menzies D, Migliori GB, Milstein MB, Mishustin SP, Pagano M, Quelapio MI, Shean K, Shin SS, Tolman AW, van der Walt ML, Van Deun A, Viiklepp P; Collaborative Group for Analysis of Bacteriology Data in MDR-TB Treatment.

Eur Respir J. 2016 Oct;48(4):1160-1170. doi: 10.1183/13993003.00462-2016. Epub 2016 Sep 1.

21.

Gatifloxacin for short, effective treatment of multidrug-resistant tuberculosis.

Chiang CY, Van Deun A, Rieder HL.

Int J Tuberc Lung Dis. 2016 Sep;20(9):1143-7. doi: 10.5588/ijtld.15.0884.

PMID:
27510237
22.

Sputum bacterial load predicts multidrug-resistant tuberculosis in retreatment patients: a case-control study.

Sander MS, Vuchas CY, Numfor HN, Nsimen AN, Abena JL, Noeske J, Van Deun A, Morgan KL.

Int J Tuberc Lung Dis. 2016 Jun;20(6):793-9. doi: 10.5588/ijtld.15.0259.

PMID:
27155183
23.

Read the new microscopy handbook: even the Ziehl-Neelsen technique has changed.

Angra P, Ridderhof J, Tahseen S, Van Deun A.

Int J Tuberc Lung Dis. 2016 Apr;20(4):567. doi: 10.5588/ijtld.16.0009. No abstract available.

24.

Use of Xpert(®) MTB/RIF assay in the first national anti-tuberculosis drug resistance survey in Pakistan.

Tahseen S, Qadeer E, Khanzada FM, Rizvi AH, Dean A, Van Deun A, Zignol M.

Int J Tuberc Lung Dis. 2016 Apr;20(4):448-55. doi: 10.5588/ijtld.15.0645.

PMID:
26970152
25.

Correlation of different phenotypic drug susceptibility testing methods for four fluoroquinolones in Mycobacterium tuberculosis.

Coeck N, de Jong BC, Diels M, de Rijk P, Ardizzoni E, Van Deun A, Rigouts L.

J Antimicrob Chemother. 2016 May;71(5):1233-40. doi: 10.1093/jac/dkv499. Epub 2016 Feb 6.

26.

Specific gyrA gene mutations predict poor treatment outcome in MDR-TB.

Rigouts L, Coeck N, Gumusboga M, de Rijk WB, Aung KJ, Hossain MA, Fissette K, Rieder HL, Meehan CJ, de Jong BC, Van Deun A.

J Antimicrob Chemother. 2016 Feb;71(2):314-23. doi: 10.1093/jac/dkv360. Epub 2015 Nov 24.

27.

Policy Guidance on Drug-Susceptibility Testing (DST) of Second-Line Antituberculosis Drugs.

Barrera L, Cooreman E, de Dieu Iragena J, Drobniewski F, Duda P, Havelkova M, Hoffner S, Kam KM, Kim SJ, Labelle S, Lambregts K, Leimane V, Nunn P, Ramsay A, Raviglione M, Rich M, Ridderhof J, Rodrigues F, Rüsch-Gerdes S, Salfinger M, Scholten J, Selvakumar N, Shinnick T, Shul'gina M, Šķenders G, Sloutsky A, Small P, Van Deun A, Varaine F, Yagui M, Vincent V, Weyer K, Wright A, Zignol M.

Geneva: World Health Organization; 2008.

28.

Disputed rpoB mutations can frequently cause important rifampicin resistance among new tuberculosis patients.

Van Deun A, Aung KJ, Hossain A, de Rijk P, Gumusboga M, Rigouts L, de Jong BC.

Int J Tuberc Lung Dis. 2015 Feb;19(2):185-90. doi: 10.5588/ijtld.14.0651.

PMID:
25574917
29.

Anti-tuberculosis drug resistance in Bangladesh: reflections from the first nationwide survey.

Kamal SM, Hossain A, Sultana S, Begum V, Haque N, Ahmed J, Rahman TM, Hyder KA, Hossain S, Rahman M, Ahsan CR, Aung KJ, Islam A, Hasan R, Van Deun A.

Int J Tuberc Lung Dis. 2015 Feb;19(2):151-6. doi: 10.5588/ijtld.14.0200. Erratum in: Int J Tuberc Lung Dis. 2015 May;19(5):622. Chowdhury, R A [corrected to Ahsan, Chowdhury R].

PMID:
25574912
30.

Is frontloaded sputum microscopy an option in active tuberculosis case finding?

Lorent N, Buyze J, Kim T, Kong C, Van Deun A, Colebunders R, Thai S, Lynen L, Rigouts L.

Int J Tuberc Lung Dis. 2015 Jan;19(1):91-6. doi: 10.5588/ijtld.14.0388.

PMID:
25519797
31.

High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses.

Piubello A, Harouna SH, Souleymane MB, Boukary I, Morou S, Daouda M, Hanki Y, Van Deun A.

Int J Tuberc Lung Dis. 2014 Oct;18(10):1188-94. doi: 10.5588/ijtld.13.0075.

PMID:
25216832
32.

Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients.

Aung KJ, Van Deun A, Declercq E, Sarker MR, Das PK, Hossain MA, Rieder HL.

Int J Tuberc Lung Dis. 2014 Oct;18(10):1180-7. doi: 10.5588/ijtld.14.0100.

PMID:
25216831
33.

Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial.

Nunn AJ, Rusen ID, Van Deun A, Torrea G, Phillips PP, Chiang CY, Squire SB, Madan J, Meredith SK.

Trials. 2014 Sep 9;15:353. doi: 10.1186/1745-6215-15-353.

34.

An operational study comparing microscopes and staining variations for tuberculosis LED FM.

Van Deun A, Aung KJ, Khan MH, de Jong BC, Gumusboga M, Hossain MA.

Int J Tuberc Lung Dis. 2014 Aug;18(8):964-71. doi: 10.5588/ijtld.14.0077.

PMID:
25199013
35.

Pseudo-outbreak of pre-extensively drug-resistant (Pre-XDR) tuberculosis in Kinshasa: collateral damage caused by false detection of fluoroquinolone resistance by GenoType MTBDRsl.

Kaswa MK, Aloni M, Nkuku L, Bakoko B, Lebeke R, Nzita A, Muyembe JJ, de Jong BC, de Rijk P, Verhaegen J, Boelaert M, Ieven M, Van Deun A.

J Clin Microbiol. 2014 Aug;52(8):2876-80. doi: 10.1128/JCM.00398-14. Epub 2014 May 28.

36.

Multi drug resistant tuberculosis in Mosango, a rural area in the Democratic Republic of Congo.

Kaswa MK, Bisuta S, Kabuya G, Lunguya O, Ndongosieme A, Muyembe JJ, Van Deun A, Boelaert M.

PLoS One. 2014 Apr 14;9(4):e94618. doi: 10.1371/journal.pone.0094618. eCollection 2014.

37.

Rifampin resistance missed in automated liquid culture system for Mycobacterium tuberculosis isolates with specific rpoB mutations.

Rigouts L, Gumusboga M, de Rijk WB, Nduwamahoro E, Uwizeye C, de Jong B, Van Deun A.

J Clin Microbiol. 2013 Aug;51(8):2641-5. doi: 10.1128/JCM.02741-12. Epub 2013 Jun 12.

38.

Rifampin drug resistance tests for tuberculosis: challenging the gold standard.

Van Deun A, Aung KJ, Bola V, Lebeke R, Hossain MA, de Rijk WB, Rigouts L, Gumusboga A, Torrea G, de Jong BC.

J Clin Microbiol. 2013 Aug;51(8):2633-40. doi: 10.1128/JCM.00553-13. Epub 2013 Jun 12.

39.

A poor drug-resistant tuberculosis programme is worse than no programme: time for a change.

Chiang CY, Van Deun A, Enarson DA.

Int J Tuberc Lung Dis. 2013 Jun;17(6):714-8. doi: 10.5588/ijtld.12.0989. Epub 2013 Apr 9. No abstract available.

PMID:
23575274
40.

Rapid diagnosis of rifampicin resistance: who needs confirmation?

Chiang CY, Van Deun A.

Int J Tuberc Lung Dis. 2013 Jan;17(1):2. doi: 10.5588/ijtld.12.0914. No abstract available.

PMID:
23231997
41.

In reply to 'Can LED fluorescence microscopy replace Ziehl-Neelsen microscopy in tuberculosis detection?'.

Van Deun A, Cattamanchi A, Davis JL, Ridderhof J.

Int J Tuberc Lung Dis. 2012 Nov;16(11):1558-9. doi: 10.5588/ijtld.12.0407-2. No abstract available.

PMID:
23044451
42.

Transmission of multidrug-resistant and extensively drug-resistant tuberculosis in rural Bangladesh: lessons learnt.

Gumusboga A, Aung KJ, Rigouts L, Van Deun A.

Public Health Action. 2012 Sep 21;2(3):76-8. doi: 10.5588/pha.12.0015.

43.

Fluorescein diacetate vital staining allows earlier diagnosis of rifampicin-resistant tuberculosis.

Van Deun A, Maug AK, Hossain A, Gumusboga M, de Jong BC.

Int J Tuberc Lung Dis. 2012 Sep;16(9):1174-9. doi: 10.5588/ijtld.11.0166. Epub 2012 Jun 28.

PMID:
22747903
44.

Extension of the intensive phase reduces relapse but not failure in a regimen with rifampicin throughout.

Aung KJ, Declercq E, Ali MA, Naha S, Datta Roy SC, Taleb MA, Hossain MA, Rigouts L, Gumusboga A, Van Deun A.

Int J Tuberc Lung Dis. 2012 Apr;16(4):455-61. doi: 10.5588/ijtld.11.0216.

PMID:
22640511
45.

Rifampicin-resistant Mycobacterium tuberculosis: susceptibility to isoniazid and other anti-tuberculosis drugs.

Kurbatova EV, Cavanaugh JS, Shah NS, Wright A, Kim H, Metchock B, Van Deun A, Barrera L, Boulahbal F, Richter E, Martín-Casabona N, Arias F, Zemanova I, Drobniewski F, Santos Silva A, Coulter C, Lumb R, Cegielski JP.

Int J Tuberc Lung Dis. 2012;16(3):355-7. doi: 10.5588/ijtld.11.0542.

46.

Global laboratory initiative tool for a stepwise process towards tuberculosis laboratory accreditation.

Datema TA, Oskam L, Engelberts MF, van Beers SM, Shinnick TM, Baker M, Ridderhof JC, Scholten J, van Deun A, Gilpin C, Klatser PR.

Int J Tuberc Lung Dis. 2012 May;16(5):704-5. doi: 10.5588/ijtld.11.0701. No abstract available.

PMID:
22507938
47.

DOT, S, or DOTS?

Van Deun A, Rieder HL.

Public Health Action. 2012 Mar 21;2(1):3-4. doi: 10.5588/pha.12.0007. No abstract available.

48.

Xpert® MTB/RIF for national tuberculosis programmes in low-income countries: when, where and how?

Trébucq A, Enarson DA, Chiang CY, Van Deun A, Harries AD, Boillot F, Detjen A, Fujiwara PI, Graham SM, Monedero I, Rusen ID, Rieder HL.

Int J Tuberc Lung Dis. 2011 Dec;15(12):1567-72. doi: 10.5588/ijtld.11.0392. Epub 2011 Oct 13.

PMID:
22005110
49.

Evaluation of the Genotype® MTBDRplus assay as a tool for drug resistance surveys.

Rigouts L, Hoza AS, De Rijk P, Torrea G, Chonde TM, Basra D, Zignol M, van Leth F, Egwaga SM, Van Deun A.

Int J Tuberc Lung Dis. 2011 Jul;15(7):959-65. doi: 10.5588/ijtld.10.0515.

PMID:
21682972
50.

Hydrochloric vs. sulphuric acid in water for Ziehl-Neelsen staining of acid-fast bacilli.

Aung KJ, Nandi P, Hamid Salim A, Hossain A, Van Deun A.

Int J Tuberc Lung Dis. 2011 Jul;15(7):955-8. doi: 10.5588/ijtld.10.0722.

PMID:
21682971

Supplemental Content

Loading ...
Support Center